Payment overview · 2025
General Payments
$298.48
16 reported records · 10 companies
Healthcare provider profile · identity verified
Scott Polster, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · HICKORY, NC · NPI 1417936048
Verified facts
What the public records show
CMS Open Payments records show Scott Polster, M.D. received $298.48 in general payments during 2025 across 16 reported records.
Boehringer Ingelheim Pharmaceuticals, Inc. accounted for 19.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Jardiance by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $59.47 | 19.9% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $47.83 | 16.0% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $47.45 | 15.9% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $25.21 | 8.4% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $25.18 | 8.4% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $21.14 | 7.1% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $21.08 | 7.1% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $18.76 | 6.3% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $16.67 | 5.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.69 | 5.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $298.48 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $59.47 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $47.83 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $47.83 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $47.45 | 4 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $25.21 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $25.21 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $25.18 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $21.14 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $21.08 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $18.76 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $16.67 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $15.69 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 41 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
13 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 624 | 158 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 225 | 60 |
| Pantoprazole Sodium | Pantoprazole Sodium | 211 | 56 |
| Levothyroxine Sodium | Levothyroxine Sodium | 199 | 47 |
| Ezetimibe | Ezetimibe | 189 | 48 |
| Amlodipine Besylate | Amlodipine Besylate | 183 | 48 |
| Omeprazole | Omeprazole | 179 | 49 |
| Losartan Potassium | Losartan Potassium | 149 | 38 |
| Lisinopril | Lisinopril | 139 | 33 |
| Tamsulosin Hcl | Tamsulosin Hcl | 138 | 46 |
| Metoprolol Succinate | Metoprolol Succinate | 134 | 35 |
| Metformin Hcl Er | Metformin Hcl | 132 | 29 |
| Furosemide | Furosemide | 127 | 43 |
| Potassium Chloride | Potassium Chloride | 126 | 28 |
| Hydrochlorothiazide | Hydrochlorothiazide | 121 | 35 |
| Tramadol Hcl | Tramadol Hcl | 115 | 33 |
| Alprazolam | Alprazolam | 113 | 20 |
| Glimepiride | Glimepiride | 112 | 26 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 110 | 31 |
| Metformin Hcl | Metformin Hcl | 110 | 27 |
| Meloxicam | Meloxicam | 99 | 41 |
| Gabapentin | Gabapentin | 95 | 21 |
| Alendronate Sodium | Alendronate Sodium | 81 | 20 |
| Montelukast Sodium | Montelukast Sodium | 74 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 73 | 32 |
| Escitalopram Oxalate | Escitalopram Oxalate | 67 | 16 |
| Lorazepam | Lorazepam | 67 | 12 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 63 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 63 | 15 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 60 | suppressed |
| Januvia | Sitagliptin Phosphate | 60 | suppressed |
| Ramipril | Ramipril | 57 | 13 |
| Simvastatin | Simvastatin | 56 | 16 |
| Atenolol | Atenolol | 54 | 11 |
| Ozempic | Semaglutide | 53 | suppressed |
| Fenofibrate | Fenofibrate | 49 | 13 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 49 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 48 | 12 |
| Synthroid | Levothyroxine Sodium | 48 | suppressed |
| Carvedilol | Carvedilol | 45 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 45 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 44 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 43 | 13 |
| Famotidine | Famotidine | 42 | suppressed |
| Jardiance | Empagliflozin | 41 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 39 | 11 |
| Allopurinol | Allopurinol | 36 | suppressed |
| Probenecid | Probenecid | 36 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 33 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 32 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 32 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 29 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 29 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Clonazepam | Clonazepam | 28 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 28 | suppressed |
| Myrbetriq | Mirabegron | 27 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 26 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 26 | suppressed |
| Klor-Con M20 | Potassium Chloride | 24 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 24 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 23 | 21 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 23 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 23 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 23 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 22 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 22 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 22 | suppressed |
| Pregabalin | Pregabalin | 21 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 21 | suppressed |
| Prednisone | Prednisone | 20 | 17 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 19 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Celecoxib | Celecoxib | 17 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 17 | suppressed |
| Novolog Flexpen | Insulin Aspart | 17 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 16 | 12 |
| Finasteride | Finasteride | 15 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 15 | suppressed |
| Telmisartan | Telmisartan | 15 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 14 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 14 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Eliquis | Apixaban | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Levofloxacin | Levofloxacin | 12 | 12 |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 12 | suppressed |
| Armodafinil | Armodafinil | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $298.48 · 16 records | Boehringer Ingelheim Pharmaceuticals, Inc. | AREXVY, CAPLYTA, Cologuard Collection Kit, Dexcom G6 Transmitter, FREESTYLE LIBRE 3, JARDIANCE, NURTEC ODT, REXULTI, TRELEGY ELLIPTA, TRINTELLIX, VOQUEZNA, ZAVZPRET | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error